|
Of the 30 included RCTs, only one10 was conducted in adolescents (aged 10 to 18 years). Baseline duration of illness for the adult studies ranged from 711 to 2212 years (weighted mean [SD] 15.6 [4.8]). A broad range of antipsychotic doses were used in the included trials. Common outcome measures included schizophrenia symptom scales (e.g., Positive and Negative Symptoms Scale [PANSS], Brief Psychiatric Rating Scale [BPRS] scores, Clinical Global Impression [CGI]), response rate, cognition, withdrawals, and serious adverse events. No evidence was available for relapse or remission rates.
|